All In Biotech

Drug Trial Radar · NCT05843916

Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease

Phase III, Open-label, Switch Over Trial of the Efficacy and Safety of Agalsidase Beta Biosidus (AGA BETA BS) in Fabry Disease Patients Previously Stabilized With Fabrazyme®

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20

Actual

Start

Dec 13, 2022

Primary completion

Sep 19, 2024

Study completion Mar 31, 2025

Sponsor

Lead sponsor
Bio Sidus SAIndustry
Sponsor type
Industry
Collaborators
Amsterdam UMC; IQVIA Pty Ltd; IQVIA RDS Inc.
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BIO-AGA-Fase III-001 is a Phase III, prospective, multicenter, open-label, single-group, baseline-controlled, switch over clinical trial to evaluate the efficacy and safety of AGA BETA BS in patients with FD already treated and previously stabilized with Fabrazyme®.

Conditions

  • Fabry Disease

Interventions

  • Recombinant human alpha galactosidase A (agalsidase beta)Drug

    All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks

  • Recombinant human alpha-galactosidase A (agalsidase beta)Drug

    All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Lyso Gb3 Serum LevelsTime frame: Baseline (after 5 week lead-in period on Fabrazyme®) and 26 weeks (after the switch to AGA BETA BS)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto de Investigaciones Clínicas Quilmes

    Buenos Aires, Argentina

  • Clínica Universitaria Reina Fabiola

    Córdoba, Argentina

  • Centro Oncológico Riojano Integral

    La Rioja, Argentina

  • Instituto de Nefrología Pergamino S.R.L

    Pergamino, Buenos Aires, Argentina

  • Centro Médico Santa María de la Salud

    San Isidro, Buenos Aires, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.